Federation Des Caisses Desjardins Du Quebec Humanigen, Inc Transaction History

Federation Des Caisses Desjardins Du Quebec

  • $18.9 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Aug 14, 2024
SELL
$0.01 - $0.2 $5 - $104
-520 Closed
0 $0
Q4 2022

Aug 14, 2024
SELL
$0.09 - $0.2 $97 - $216
-1,080 Reduced 67.5%
520 $62,000
Q1 2022

Aug 14, 2024
BUY
$1.81 - $3.97 $2,896 - $6,352
1,600 New
1,600 $4.82 Million
Q2 2021

Aug 30, 2024
BUY
$13.54 - $22.74 $21,664 - $36,384
1,600 New
1,600 $27.8 Million
Q4 2020

Aug 30, 2024
BUY
$7.97 - $21.66 $12,752 - $34,656
1,600 New
1,600 $28 Million

Others Institutions Holding HGEN

# of Institutions
4
Shares Held
558K
Call Options Held
0
Put Options Held
0
View Full List

About HUMANIGEN, INC

HGEN Quotes by TradingView
  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email